Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23641693 | 0.82 | GRIN2D (0.36) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL24091187 | 0.80 | GRIN2D (0.39) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL17009537 | 0.77 | GRIN2D (0.33) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL10205046 | 0.77 | GRIN2D (0.38) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL17734308 | 0.77 | KDM4E (0.32) | — | |
| SCHEMBL12026500 | 0.77 | GRIN2D (0.38) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL12026493 | 0.76 | PDE10A (0.34) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL16862211 | 0.75 | GRIN2D (0.37) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL17791235 | 0.72 | — | — | |
| SCHEMBL9397043 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230265100-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11667643-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667643-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220009936-A1 | RIP1K INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-01-13 | — | — | US | disclosed |
| US-20210317135-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | GRIN2D 3665/4885GRIN3B 2257/4885CHRM2 4674/4885 |
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | GRIN2D 3221/4885GRIN3B 1925/4885CHRM2 4622/4885 |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | GRIN2D 3221/4885GRIN3B 1925/4885CHRM2 4622/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | GRIN2D 3665/4885GRIN3B 2257/4885CHRM2 4674/4885 |
| US-20230265100-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | GRIN2D 3665/4885GRIN3B 2257/4885CHRM2 4674/4885 |
| US-20220009936-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | GRIN2D 3665/4885GRIN3B 2257/4885CHRM2 4674/4885 |
| US-11667643-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | GRIN2D 3665/4885GRIN3B 2257/4885CHRM2 4674/4885 |
| US-20210317135-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | GRIN2D 3665/4885GRIN3B 2257/4885CHRM2 4674/4885 |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | GRIN2D 3221/4885GRIN3B 1925/4885CHRM2 4622/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | GRIN2D 3665/4885GRIN3B 2257/4885CHRM2 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.